Search clinical trials for: AZD5335
Total 110 results
-
AstraZenecaRecruitingOvarian Cancer | Lung AdenocarcinomaUnited States, China, Spain, Canada, Australia, Taiwan, Israel, Japan, United Kingdom
-
AstraZenecaCompletedSafety and Tolerability, | Advanced Solid Malignancy, | Pharmacokinetics, Pharmacodynamics, | Tumour Response,United Kingdom, Netherlands
-
AstraZenecaRecruitingMultiple MyelomaUnited States, Spain, Australia, Canada, France, China, Japan, Germany
-
AstraZenecaCompletedAdvanced Solid Tumor | Advanced Solid MalignancyJapan
-
AstraZenecaCompleted
-
AstraZenecaCompleted
-
Children's Hospital Medical Center, CincinnatiCompleted
-
AstraZenecaCompletedIdiopathic Pulmonary FibrosisUnited States
-
AstraZenecaCompletedHealthy ParticipantsUnited States
-
AstraZenecaCompletedAnxiety DisordersUnited States
-
AstraZenecaCompleted
-
AstraZenecaCompletedHealthy VolunteerUnited States
-
AstraZenecaTerminated
-
AstraZenecaCompletedAdvanced Solid MalignanciesJapan
-
AstraZenecaSuspendedMetabolism | Absorption | Distribution | ExcretionUnited Kingdom
-
AstraZenecaCompletedHealthyUnited Kingdom
-
AstraZenecaCompleted
-
National Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple MyelomaUnited States
-
AstraZenecaQuotient SciencesCompleted
-
AstraZenecaParexelCompletedPulmonary/Respiratory DiseasesUnited States
-
AstraZenecaCompletedAtrial FibrillationSweden, Czech Republic, Hungary, Poland, Netherlands, Norway, Denmark, Slovakia
-
AstraZenecaCompletedAtrial FibrillationRussian Federation, Poland, Denmark, Norway, Slovakia, Sweden
-
AstraZenecaCompletedMetastatic Castrate-Resistant Prostate Cancer (mCRPC), | Efficacy, | Safety and Tolerability, | Pharmacokinetics, | Pharmacodynamics, | Tumour Response.United Kingdom, United States
-
Institute of Cancer Research, United KingdomRoyal Marsden NHS Foundation TrustUnknownAdenocarcinoma of the ProstateUnited Kingdom
-
University of California, Los AngelesCompletedAutism Spectrum DisorderUnited States
-
AstraZenecaRecruitingProstate CancerUnited States, Spain, United Kingdom, Netherlands, Canada, Australia
-
AstraZenecaCompleted
-
University College, LondonCompleted
-
AstraZenecaParexelCompleted
-
University of NottinghamAstraZeneca; Cancer Research UK; National Cancer Research NetworkCompleted
-
AstraZenecaCompleted
-
University of Michigan Rogel Cancer CenterTerminatedProstate CancerUnited States
-
AstraZenecaActive, not recruitingCervical Cancer | Ovarian Cancer | Pharmacokinetics | Endometrial Cancer | Pharmacodynamics | Safety and Tolerability | Advanced Solid Malignancy | Tumour Response | Advanced or Metastatic Breast Cancer | PIK3CA | AKT1 | PTEN | ER Positive | HER2 PositiveUnited States, Italy, Canada, France, Japan, United Kingdom, Spain, Netherlands, Denmark, Singapore
-
AstraZenecaCompletedAdvanced Solid Tumours With Androgen Receptor Pathway as a Potential FactorUnited Kingdom, United States
-
AstraZenecaCompleted
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI); GlaxoSmithKline; Genentech, Inc.; Brain Science...RecruitingIntracranial Meningioma | Recurrent Meningioma | NF2 Gene MutationUnited States
-
AstraZenecaCompleted
-
AstraZenecaParexelCompleted
-
AstraZenecaCompletedLeft Ventricle FunctionSweden
-
National Taiwan University HospitalMinistry of Science and Technology, TaiwanUnknownGastroesophageal Reflux DiseaseTaiwan
-
AstraZenecaParexelCompletedProgressive Metastatic Castrate-Resistant Prostate CancerUnited States, Spain, Belgium, France, Korea, Republic of
-
University College, LondonCompleted
-
AstraZenecaCompletedAdvanced Solid Malignancies | Breast Cancer - ER+, HER2 - | Breast Cancer - ER+, HER2-, PIK3CA Gene MutationUnited States, United Kingdom
-
AstraZenecaQuotient SciencesCompleted
-
University Hospital Southampton NHS Foundation...AstraZeneca; Cancer Research UKCompletedProstate CancerUnited Kingdom